Clinical trial
A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With…
NCT00372112 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00372112 |
|---|---|
| Title | A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
| Official title | A 2-wk Study to Evaluate the Safety, Tolerability,Pharmacodynamics and Pharmacokinetics of GW642444H(100 Administered Once Daily in the Morning Via DISKUS™ Dry-powder Inhaler)Compared With SEREVENT(Salmeterol)(50mcg Administered Twice Daily Via DISKUS Dry-powder Inhaler)and Placebo in Subject w/COPD |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug, Other |
| Interventions | GW642444, Placebo |
| Enrollment | 68 |
| Start date | Nov 3, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 10, 2007 |
| First posted | Sep 6, 2006 |
| Last update posted | Apr 2, 2018 |
| Countries | Australia, Bulgaria, Germany, Netherlands, New Zealand, Romania |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: